HOFFMANN EITLE welcomes new partner to the London office
News | 10.01.2023
We are pleased to announce that David Miller has joined the firm as a partner in the biotechnology team, based in the London office.
David brings over 15 years of practice in the field of patent law, with a particular focus on biotechnology, pharmaceuticals and diagnostics. Recommended as a leading attorney in Who's Who Legal 2022 guide, David has a strong track record of successfully securing patents for his clients. David also has extensive experience in opposition proceedings at the European Patent Office (EPO), and has defended patents protecting products such as Imbruvica® (ibrutinib), Kadcyla® (trastuzumab emtansine), Lemtrada® (alemtuzumab), Eloctate® (recombinant Factor VIII) and Alprolix® (recombinant Factor IX).
"We are thrilled to welcome David to our team," said James Ogle, partner in the biotechnology team at HOFFMANN EITLE. "His expertise in biotechnology patent law will be a valuable asset to our clients, and we are confident that he will make significant contributions to the growth and success of our firm."
HOFFMANN EITLE is a leading provider of patent prosecution and litigation services. The addition of David as a partner in the London office further enhances the firm's capabilities in the biotechnology sector and underscores the firm's commitment to expanding its presence in the region.